Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIOIU8)

Drug Name
GSK4428859 Drug Info
Synonyms EOS884448
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMIOIU8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting V-set and immunoglobulin domain-containing protein 9 (TIGIT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ociperlimab DMEDSVJ Non-small-cell lung cancer 2C25.Y Phase 3 [2]
AB154 DMUES7Y Non-small-cell lung cancer 2C25 Phase 3 [3]
Rilvegostomig DMDWCM2 Non-small-cell lung cancer 2C25 Phase 1/2 [4]
ASP8374 DMA71OL Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
SEA-TGT DM7GUH3 Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
COM902 DMR6T8L Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
M6223 DM6J085 Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
V-set and immunoglobulin domain-containing protein 9 (TIGIT) TTWNL74 TIGIT_HUMAN Not Available [1]

References

1 Clinical pipeline report, company report or official report of GlaxoSmithKline
2 Clinical pipeline report, company report or official report of BeiGene.
3 Clinical pipeline report, company report or official report of Arcus Biosciences.
4 ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of Seagen.
7 COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26.
8 ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health.